School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Jhb, South Africa.
Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, SA Medical Research Council and University of the Witwatersrand, Jhb, South Africa; National Institute for Communicable Diseases, Jhb, South Africa.
Vaccine. 2023 Jun 1;41(24):3617-3626. doi: 10.1016/j.vaccine.2023.04.051. Epub 2023 May 9.
Subunit vaccines for the Hepatitis B virus (HBV) have greatly reduced the prevalence of infection and morbidity through HBV-related liver cirrhosis and cancer. However, strength of immune response to vaccination varies considerably. While it is known that ABO blood types may influence HBV infection risk, the role of ABO and related blood types in strength of immune response to HBV vaccine has not been investigated. We examined 16 polymorphisms in the ABO, FUT2, and FUT3 genes and their related phenotypes for associations with strength of antibody response to HBV vaccine in Black South African infants. Anti-HBc and anti-HBs antibody levels were measured by CMIA assay 1-3 months after the last dose of HBV vaccine. Prior infection occurred in 8/207 individuals (3.86%) who were removed from further study. Of the remaining 199 individuals, 83.4% individuals were strong responders (anti-HBs ≥ 100 mIU/ml, median 973 mIU/ml), another 15.6% were weak responders (anti-HBs < 100 mIU/ml, median 50 mIU/ml) and 1% were non-responders (anti-HBs < 10 mIU/ml). The frequency of weak responders to HBV vaccine was not significantly affected by sex, birthweight, use of an additional booster dose of vaccine or cohort of origin. We characterised patterns of genetic variation present at the ABO, FUT2 and FUT3 loci by use of MassArray genotyping and used these data to predict ABO, Secretor and Lewis phenotypes. We observed significant association of ABO blood type with strength of antibody response to HBV vaccine in a Black South African cohort (p = 0.002). In particular, presence of rs8176747G and expression of B antigen (whether in B blood type or AB blood type) was associated with decreased antibody response to HBV vaccine. Secretor and Lewis blood types were not associated with antibody response to HBV vaccine. This work increases our understanding of the impact that host genetic variation may have on vaccine immunogenicity.
乙型肝炎病毒 (HBV) 的亚单位疫苗通过与 HBV 相关的肝硬化和肝癌大大降低了感染和发病的发生率。然而,疫苗接种的免疫反应强度差异很大。虽然已知 ABO 血型可能影响 HBV 感染风险,但 ABO 及相关血型在 HBV 疫苗免疫反应强度中的作用尚未得到研究。我们研究了 16 个 ABO、FUT2 和 FUT3 基因的多态性及其相关表型与南非黑人婴儿对 HBV 疫苗的抗体反应强度的关系。在接种 HBV 疫苗最后一剂后 1-3 个月,通过 CMIA 检测抗-HBc 和抗-HBs 抗体水平。在 207 人中,有 8 人(3.86%)发生了先前感染,因此被排除在进一步研究之外。在其余 199 人中,83.4%的人是强应答者(抗-HBs≥100 mIU/ml,中位数为 973 mIU/ml),15.6%的人是弱应答者(抗-HBs<100 mIU/ml,中位数为 50 mIU/ml),1%的人是无应答者(抗-HBs<10 mIU/ml)。HBV 疫苗的弱应答者频率不受性别、出生体重、是否使用额外的疫苗加强剂量或来源队列的影响。我们通过 MassArray 基因分型来描述 ABO、FUT2 和 FUT3 基因座上存在的遗传变异模式,并利用这些数据来预测 ABO、分泌型和 Lewis 表型。我们观察到在南非黑人队列中,ABO 血型与 HBV 疫苗抗体反应强度之间存在显著关联(p=0.002)。特别是,rs8176747G 的存在和 B 抗原的表达(无论是在 B 血型还是 AB 血型中)与 HBV 疫苗的抗体反应降低有关。分泌型和 Lewis 血型与 HBV 疫苗的抗体反应无关。这项工作增加了我们对宿主遗传变异可能对疫苗免疫原性产生影响的理解。